The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

425Citations
Citations of this article
97Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either "atypical" myeloproliferative disorders (MPDs) or the myelodysplastic syndromes (MDSs) is unknown. Bone marrow-derived genomic DNA from 245 patients-119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophilic leukemia (CNL)-was screened for the JAK2 V617F mutation. A mutant allele was detected in 11 patients: 3 with CMML (3%), 5 with MDS (5%), 2 with SM, and 1 with CNL. Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of lymphoma, and this patient with SM also had associated myelofibrosis and CMML. The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders. © 2005 by The American Society of Hematology.

Figures

References Powered by Scopus

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

4665Citations
N/AReaders
Get full text

Proposals for the classification of the myelodysplastic syndromes

3838Citations
N/AReaders
Get full text

A gain-of-function mutation of JAK2 in myeloproliferative disorders

3191Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes

3802Citations
N/AReaders
Get full text

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1094Citations
N/AReaders
Get full text

MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients

896Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Steensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F., Levine, R. L., … Tefferi, A. (2005). The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood, 106(4), 1207–1209. https://doi.org/10.1182/blood-2005-03-1183

Readers over time

‘09‘10‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2506121824

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 34

55%

Researcher 14

23%

Professor / Associate Prof. 13

21%

Lecturer / Post doc 1

2%

Readers' Discipline

Tooltip

Medicine and Dentistry 30

43%

Biochemistry, Genetics and Molecular Bi... 21

30%

Agricultural and Biological Sciences 13

19%

Pharmacology, Toxicology and Pharmaceut... 5

7%

Save time finding and organizing research with Mendeley

Sign up for free
0